Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

被引：0
|
作者：
Eef Hoeben
Willem De Winter
Martine Neyens
Damayanthi Devineni
An Vermeulen
Adrian Dunne
机构：
[1] Janssen Research and Development,Model Based Drug Development, Quantitative Sciences
[2] A Division of Janssen Pharmaceutica NV,Clinical Pharmacology, Quantitative Sciences
[3] Janssen Research and Development LLC,undefined
来源：
Clinical Pharmacokinetics | 2016年 / 55卷
关键词：
SGLT2 Inhibitor; Canagliflozin; Objective Function Value; Normalize Prediction Distribution Error; popPK Model;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：209 / 223
页数：14
相关论文
共 50 条
  • [1] Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus
    Hoeben, Eef
    De Winter, Willem
    Neyens, Martine
    Devineni, Damayanthi
    Vermeulen, An
    Dunne, Adrian
    [J]. CLINICAL PHARMACOKINETICS, 2016, 55 (02) : 209 - 223
  • [2] Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
    Kun Wang
    Lingge Feng
    Jiayi Zhang
    Quanfei Zou
    Fengyan Xu
    Zhongyi Sun
    Fuxing Tang
    Li Chen
    [J]. Clinical Pharmacokinetics, 2023, 62 : 1413 - 1425
  • [3] Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
    Fediuk, Daryl J.
    Zhou, Susan
    Dawra, Vikas Kumar
    Sahasrabudhe, Vaishali
    Sweeney, Kevin
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 696 - 706
  • [4] Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
    Wang, Kun
    Feng, Lingge
    Zhang, Jiayi
    Zou, Quanfei
    Xu, Fengyan
    Sun, Zhongyi
    Tang, Fuxing
    Chen, Li
    [J]. CLINICAL PHARMACOKINETICS, 2023, 62 (10) : 1413 - 1425
  • [5] Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
    Triplitt, Curtis
    Cornell, Susan
    [J]. CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2015, 8 : 73 - 81
  • [6] Population pharmacokinetic analysis of dapagliflozin in healthy and subjects with type 2 diabetes mellitus.
    Feng, Y.
    Zhang, L.
    Komoroski, B.
    Pfister, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S93 - S93
  • [7] Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
    Nobuya Inagaki
    Kazuoki Kondo
    Toru Yoshinari
    Manabu Ishii
    Masaki Sakai
    Hideki Kuki
    Kenichi Furihata
    [J]. Clinical Drug Investigation, 2014, 34 : 731 - 742
  • [8] Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
    Inagaki, Nobuya
    Kondo, Kazuoki
    Yoshinari, Toru
    Ishii, Manabu
    Sakai, Masaki
    Kuki, Hideki
    Furihata, Kenichi
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (10) : 731 - 742
  • [9] Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus
    Zhao, Charlie
    Vaidyanathan, Sujata
    Yeh, Ching-Ming
    Maboudian, Mojdeh
    Dieterich, Hans Armin
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (11) : 1125 - 1134
  • [10] Psychophysical evaluation of temperature sensation in healthy volunteers and patients with diabetes mellitus type 2
    Odriozola, A
    Valls-Solé, J
    [J]. JOURNAL OF NEUROLOGY, 2004, 251 : 47 - 47
12345